Generics Partnerships Oakrum has launched generic Cystadane with ANI and SunGen, indicating a proven capability to execute joint generic launches and pursue new co-development opportunities with rare-disease products.

Rare Disease Focus With a clear focus on affordable therapies for rare and specialty patients, Oakrum presents opportunities to partner with specialty distributors, patient groups, and hospital systems seeking niche medicines with unmet needs.

US Exclusivity Advantage The 180 days of exclusivity tied to the Cystadane generic provides a compelling value proposition for partners seeking protected windows to establish market access and early revenue in the US.

Lean Manufacturing Partner Oakrum's track record of launching generics such as pyrimethamine and methylprednisolone suggests a capable, potentially lean manufacturing and supply partner for other organizations looking to outsource or co-manufacture generic products.

Regional Digital Reach Based in St. Louis with a tech stack including cloud and analytics tools, Oakrum could be a targeted collaborator for regional distributors and data-driven launches in the US Midwest, leveraging digital marketing and patient access programs.